Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Pliant Therapeutics (PLRX) FCF Margin (2020 - 2023)

Pliant Therapeutics has reported FCF Margin over the past 4 years, most recently at 10226.61% for Q2 2023.

  • Quarterly FCF Margin fell 975053.0% to 10226.61% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 47825.0% through Mar 2024, down 4676104.0% year-over-year, with the annual reading at 7422.91% for FY2023, 644582.0% down from the prior year.
  • FCF Margin was 10226.61% for Q2 2023 at Pliant Therapeutics, down from 2285.21% in the prior quarter.
  • Over five years, FCF Margin peaked at 207.94% in Q2 2020 and troughed at 10226.61% in Q2 2023.
  • The 4-year median for FCF Margin is 1002.07% (2021), against an average of 1585.05%.
  • Year-over-year, FCF Margin soared 59954bps in 2022 and then plummeted -975053bps in 2023.
  • A 4-year view of FCF Margin shows it stood at 352.25% in 2020, then crashed by -164bps to 928.51% in 2021, then crashed by -62bps to 1508.65% in 2022, then plummeted by -578bps to 10226.61% in 2023.
  • Per Business Quant, the three most recent readings for PLRX's FCF Margin are 10226.61% (Q2 2023), 2285.21% (Q1 2023), and 1508.65% (Q4 2022).